An interventional study of stool sampling and stool sampling in Spondyloarthritis, sponsored by Hôpital Européen Marseille. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-25.
Sponsored by Hôpital Européen Marseille · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Spondylarthritis with a site in France — 17 open to participants now, 19 under way, none of them phase 3. Spondylarthritis · France.
Among the 73 studies in Spondylarthritis with a site in France, this one is the 25th largest by planned enrollment of the 36 interventional ones that give a count, is one of 8 that started in 2019, is one of 31 with no phase, reaches primary completion later than 4 of the 18 other live ones, and was the 51st registered.
203 studies on the registry are indexed under Spondylarthritis; 52 are open to participants now.
Browse Spondylarthritis studies →17 of the 73 studies in Spondylarthritis with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–75
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Association de Recherche Clinique en Rhumatologie · Sites in France
Ages 18–80
Hospices Civils de Lyon · Sites in France
Ages 18+
Institut Pasteur · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 37 Spondylarthritis studies recruiting now, 20 (54%) set no upper age limit and 9 (24%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 8 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 108 across 106 interventional studies indexed under Spondylarthritis.
Median enrollment 108 across the 36 interventional studies, 400 across the 37 observational. Of the 43 that completed or were terminated, 4 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 73 have an industry lead sponsor. The 10 most frequent:
Hôpital Européen Marseille is the lead sponsor of 30 studies on the registry; 8 are open to participants now.
Hôpital Européen Marseille has 1 study filed under Spondylarthritis — fewer than ten, so there is no comparison to draw.
6 of the studies in Spondylarthritis with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04292067Assistance Publique - Hôpitaux de ParisCharacterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis | 2026-11 |
| NCT07141017Association de Recherche Clinique en RhumatologieInitial Standardized Global Review in Axial Spondyloarthritis | 2027-05 |
| NCT07077304Assistance Publique - Hôpitaux de ParisEACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases | 2027-08-31 |
| NCT07460739Assistance Publique - Hôpitaux de ParisEfficacy of a Self-Management Smartphone App to Improve Safety Skills in Patients With Inflammatory Arthritis | 2027-09 |
| NCT05290363Institut PasteurThe Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis | 2027-09-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 73 studies in Spondylarthritis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Spondyloarthritis (SpA) is a group of inflammatory rheumatic disorders that mainly manifested by inflammatory pain of the spine, pelvis and sometimes limbs. Classically, SpA has been classified into several subtypes, such as ankylosing spondylitis (AS), psoriatic arthritis (PsA), inflammatory bowel disease (IBD)-associated.
Several studies have shown specific changes in the gut microbiota during SpA. A recent, uncontrolled study suggested that the therapeutic response to anti-TNFα (Tumor Necrosis Factor) therapy could be predicted by analysis of the gut microbiota.
The purpose of the study MEDIBIOTE 3 is to confirm that in SpA, the composition of the intestinal microbiota at the initiation of treatment is predictive of the response to treatment with biotherapy (anti-TNFα / anti-IL17).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For patient with spondyloarthritis:
For control Subject:
Exclusion Criteria:
Other: stool sampling
Other: stool sampling
Participants will provide two stool samples: one collected the day of inclusion and a second, four months later after anti-TNF α or anti- IL-17 (interleukin-17) treatment initiation.
Participants will provide one stool sample at inclusion
Variability in the qualitative and quantitative composition of intestinal microbiota in patients responding to biotherapy compared to the group of non-responding patients
Time frame: 18 Months
Differences on intestinal microbiota composition (qualitative and quantitative) of patients with Spa versus healthy controls.
Time frame: 18 Months
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2019 (actual). Primary completion is estimated for May 2026, 81 months after the start.
Of 44 non-industry interventional studies with no phase under Spondylarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 77. This study's planned 81 months is above that.
Counting every sponsor, half of 46 studies reached it within 30 months; a quarter within 16 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hôpital Européen Marseille